P2K Bio MOU signing ceremony (1).jpg

 

P2K Bio MOU signing ceremony (2).jpg

 

 

 

KyungDong Pharm signed an agreement with P2K Bio to develop a treatment for dry eye disease. The ceremony took place on May 27 at the Gwacheon headquarters, attended by KyungDong Pharm CEOs Ryu Ki-sung and Kim Kyung-hoon, P2K Bio CEO Park Yoon-sang and senior representatives of both companies. The MOU covers cooperation on the research, development and commercialization of dry eye treatments, as well as other related activities. CEO Ryu said, “This agreement with P2K Bio will establish a foundation for developing a dry eye treatment. We hope to expand our product portfolio by adding ophthalmic medicines to KyungDong Pharm’s pipeline.” Founded in 2022, P2K Bio is a pharmaceutical and biotechnology venture focused on medical and pharmaceutical R&D. It is developing formulation technologies for small-molecule and biological medicines, pulmonary drug delivery technologies and microneedle platforms. The companies plan to work closely on new product development, including nonclinical and clinical studies, and achieve their development milestones in sequence.